newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

  • IGC Pharma (NYSE: IGC) announced that CEO Ram Mukunda & CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.
  • Management will discuss recent clinical progress in the Phase 2 CALMA trial for IGC-AD1 regarding agitation associated with Alzheimer's disease, including enrollment momentum & regulatory developments.
  • The discussion will cover advancements in the Company's AI-driven precision medicine platform & progress across its broader pipeline of disease-modifying Alzheimer's candidates.
  • IGC will provide perspective on upcoming milestones & strategic priorities for fiscal 2026.
  • IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer's & metabolic disorders, with IGC-AD1 as its lead cannabinoid-based therapy.
  • The Company's pipeline includes TGR-63 targeting amyloid plaques & early-stage programs focused on neurodegeneration, tau proteins, & metabolic dysfunctions.
  • Forward-looking statements in the release are subject to risks including potential failure to commercialize products, obtain regulatory approval, or issues with AI algorithms & government regulations.
  • Contact information for IGC Pharma Investor Relations is Rosalyn Christian & John Nesbett at IMS Investor Relations.